Asthma and Chronic Obstructive Pulmonary Disease

Forno, Erick; Ortega, Victor E.; Celedón, Juan C.

doi:10.1016/j.ccm.2023.03.008

Cited by 6 publications

(3 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, our healthy donor cohort was also not matched for race, with only 10% of patients being Black, non-Hispanic subjects, whereas the asthma cohorts had 65% and 78% Black, non-Hispanic subjects in the mild-to-moderate and severe asthma groups, respectively. This could impact our capacity to draw any broad conclusions given the enhanced prevalence of asthma in U.S. Black, non-Hispanic children and the enhanced mortality of asthma in this subgroup [ 47 ]. In addition, our ER vs. PICU samples were not matched in terms of time since corticosteroids and dosing.…”

Section: Discussionmentioning

confidence: 99%

Granular Insights: Neutrophil Predominance and Elastase Release in Severe Asthma Exacerbations in a Pediatric Cohort

Henley,

Tresselt,

Hook

et al. 2024

Cells

View full text Add to dashboard Cite

The chronic inflammatory component of asthma is propagated by granulocytes, including neutrophils and eosinophils, in the peripheral circulation and airway. Previous studies have suggested that these cells have an altered expression of adhesion-related molecules and a propensity for the release of granule contents that may contribute to tissue damage and enhance inflammatory complications in patients with status asthmaticus. The goal of this prospective cohort study at a tertiary care pediatric hospital with a large population of asthma patients was to assess the role of granulocyte-based inflammation in the development of asthma exacerbation. Subjects were enrolled from two patient populations: those with mild-to-moderate asthma exacerbations seen in the emergency department and those with severe asthma admitted to the intensive care unit (PICU). Clinical data were collected, and blood was drawn. Granulocytes were immediately purified, and the phenotype was assessed, including the expression of cell surface markers, elastase release, and cytokine production. Severe asthmatics admitted to the PICU displayed a significantly higher total neutrophil count when compared with healthy donors. Moreover, little to no eosinophils were found in granulocyte preparations from severe asthmatics. Circulating neutrophils from severe asthmatics admitted to the PICU displayed significantly increased elastase release ex vivo when compared with the PMN from healthy donors. These data suggest that the neutrophil-based activation and release of inflammatory products displayed by severe asthmatics may contribute to the propagation of asthma exacerbations.

show abstract

Section: Discussionmentioning

confidence: 99%

Granular Insights: Neutrophil Predominance and Elastase Release in Severe Asthma Exacerbations in a Pediatric Cohort

Henley,

Tresselt,

Hook

et al. 2024

Cells

View full text Add to dashboard Cite

show abstract

“…Due to these advantages, nanotechnology can ensure the therapeutic efficacy of APIs in dissatisfactory situations where the patient’s condition (e.g., unconsciousness, insufficient inspiratory flow rate, breath-holding problems, and inadequate coordination with the use of inhalation devices) results in poor inhalation effectiveness. Therefore, inhalable nano-formulations are considered to have promising applications in treating COPD, asthma, lung cancer, COVID-19, and other lung diseases [ 23 , 42 , 48 , 49 ].…”

Section: Introductionmentioning

confidence: 99%

“…The global morbidity and mortality of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma have increased from 1990 to the present [22][23][24][25][26]. Despite the progress in drug discovery and clinical diagnosis, there is still a lack of effective treatments for these diseases.…”

Section: Introductionmentioning

confidence: 99%

Nano-Formulations for Pulmonary Delivery: Past, Present, and Future Perspectives

Peng,

Wang,

Zhang

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

With the development of nanotechnology and confronting the problems of traditional pharmaceutical formulations in treating lung diseases, inhalable nano-formulations have attracted interest. Inhalable nano-formulations for treating lung diseases allow for precise pulmonary drug delivery, overcoming physiological barriers, improving aerosol lung deposition rates, and increasing drug bioavailability. They are expected to solve the difficulties faced in treating lung diseases. However, limited success has been recorded in the industrialization translation of inhalable nano-formulations. Only one relevant product has been approved by the FDA to date, suggesting that there are still many issues to be resolved in the clinical application of inhalable nano-formulations. These systems are characterized by a dependence on inhalation devices, while the adaptability of device formulation is still inconclusive, which is the most important issue impeding translational research. In this review, we categorized various inhalable nano-formulations, summarized the advantages of inhalable nano-formulations over conventional inhalation formulations, and listed the inhalable nano-formulations undergoing clinical studies. We focused on the influence of inhalation devices on nano-formulations and analyzed their adaptability. After extensive analysis of the drug delivery mechanisms, technical processes, and limitations of different inhalation devices, we concluded that vibrating mesh nebulizers might be most suitable for delivering inhalable nano-formulations, and related examples were introduced to validate our view. Finally, we presented the challenges and outlook for future development. We anticipate providing an informative reference for the field.

show abstract

Residential surrounding greenness and the incidence of childhood asthma: Findings from a population-based cohort in Ontario, Canada

Mansouri,

Lavigne,

Talarico

et al. 2024

Environmental Research

View full text Add to dashboard Cite

Asthma and Chronic Obstructive Pulmonary Disease

Cited by 6 publications

References 107 publications

Granular Insights: Neutrophil Predominance and Elastase Release in Severe Asthma Exacerbations in a Pediatric Cohort

Granular Insights: Neutrophil Predominance and Elastase Release in Severe Asthma Exacerbations in a Pediatric Cohort

Nano-Formulations for Pulmonary Delivery: Past, Present, and Future Perspectives

Residential surrounding greenness and the incidence of childhood asthma: Findings from a population-based cohort in Ontario, Canada

Contact Info

Product

Resources

About